Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.
作者信息
Javanmard Shaghayegh Haghjooy, Heshmat-Ghahdarijani Kiyan, Vaseghi Golnaz
机构信息
Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
出版信息
Infect Control Hosp Epidemiol. 2021 Jan;42(1):118-119. doi: 10.1017/ice.2020.195. Epub 2020 May 4.
Abstract
摘要
相似文献
1
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.血管紧张素转换酶抑制剂（ACE抑制剂）和血管紧张素II受体阻滞剂（ARB）在COVID-19预防或治疗中的应用：一个悖论。
Infect Control Hosp Epidemiol. 2021 Jan;42(1):118-119. doi: 10.1017/ice.2020.195. Epub 2020 May 4.
2
Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.血管紧张素转化酶作为新型 SARS-CoV-2 的新免疫靶点。
Immunol Cell Biol. 2021 Feb;99(2):192-205. doi: 10.1111/imcb.12396. Epub 2020 Oct 7.
3
COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.2019冠状病毒病、高血压与肾素-血管紧张素-醛固酮系统阻滞剂：BRACE-CORONA试验
Cardiovasc Res. 2020 Dec 1;116(14):e198-e199. doi: 10.1093/cvr/cvaa325.
4
ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?血管紧张素转换酶2与严重急性呼吸综合征冠状病毒2：组织还是血浆，有益还是有害？
Am J Hypertens. 2021 Apr 2;34(3):274-277. doi: 10.1093/ajh/hpaa175.
5
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
6
Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions.酚类化合物可破坏刺突介导的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）假病毒颗粒的受体结合及进入过程。
PLoS One. 2021 Jun 17;16(6):e0253489. doi: 10.1371/journal.pone.0253489. eCollection 2021.
7
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义：美国心脏病学会评论专题周报。
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
8
Binding and entering: COVID finds a new home.结合与进入：新冠病毒找到了新家。
PLoS Pathog. 2021 Aug 30;17(8):e1009857. doi: 10.1371/journal.ppat.1009857. eCollection 2021 Aug.
9
ACE2: from protection of liver disease to propagation of COVID-19.ACE2：从保护肝脏疾病到传播 COVID-19。
Clin Sci (Lond). 2020 Dec 11;134(23):3137-3158. doi: 10.1042/CS20201268.
10
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
引用本文的文献
1
Association between infection, high‑density lipoprotein metabolism and cardiovascular health (Review).感染、高密度脂蛋白代谢与心血管健康之间的关联（综述）
Biomed Rep. 2024 Jan 18;20(3):39. doi: 10.3892/br.2024.1729. eCollection 2024 Mar.
2
RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives.与未被诊断为糖尿病且无需抗高血压治疗或使用其他抗高血压药物治疗的新冠住院患者相比，血管紧张素受体拮抗剂（RAAS 抑制剂）与新冠住院患者的生存机会增加有关。
Front Endocrinol (Lausanne). 2023 Jan 19;14:1077959. doi: 10.3389/fendo.2023.1077959. eCollection 2023.
3
COVID-19 and RAAS inhibitors: is there a final conclusion?新型冠状病毒肺炎与肾素-血管紧张素-醛固酮系统抑制剂：有最终结论了吗？
Iran J Microbiol. 2021 Dec;13(6):728-736. doi: 10.18502/ijm.v13i6.8071.
4
Use of glucocorticoids and azithromycin in the therapy of COVID-19.COVID-19 的糖皮质激素和阿奇霉素治疗。
Pharmacol Rep. 2021 Dec;73(6):1513-1519. doi: 10.1007/s43440-021-00286-4. Epub 2021 Jun 4.
5
COVID-19: breaking down a global health crisis.COVID-19：破解一场全球健康危机。
Ann Clin Microbiol Antimicrob. 2021 May 18;20(1):35. doi: 10.1186/s12941-021-00438-7.
6
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.COVID-19 住院患者的药物治疗：根据疾病严重程度的治疗模式。
Drugs. 2020 Dec;80(18):1961-1972. doi: 10.1007/s40265-020-01424-7.
7
The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis.吸烟对新冠病毒疾病症状严重程度的影响：系统评价与荟萃分析
Pulm Med. 2020 Sep 8;2020:7590207. doi: 10.1155/2020/7590207. eCollection 2020.
本文引用的文献
1
COVID-19: a fast evolving pandemic.新型冠状病毒肺炎：一场快速演变的大流行病。
Trans R Soc Trop Med Hyg. 2020 Apr 8;114(4):241-248. doi: 10.1093/trstmh/traa025.
2
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
3
COVID-19-New Insights on a Rapidly Changing Epidemic.《2019冠状病毒病——快速演变疫情的新见解》
JAMA. 2020 Apr 14;323(14):1339-1340. doi: 10.1001/jama.2020.3072.
4
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
5
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.新型冠状病毒受体识别：基于 SARS 冠状病毒长达十年结构研究的分析。
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
6
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
7
Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.中国武汉不明原因肺炎疫情：谜团与奇迹
J Med Virol. 2020 Apr;92(4):401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12.
8
Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study.急性呼吸窘迫综合征中循环血管紧张素肽水平与临床结局相关：一项初步研究。
PLoS One. 2019 Mar 7;14(3):e0213096. doi: 10.1371/journal.pone.0213096. eCollection 2019.
9
Recombinant human ACE2: acing out angiotensin II in ARDS therapy.重组人血管紧张素转换酶2：在急性呼吸窘迫综合征治疗中胜过血管紧张素II 。
Crit Care. 2017 Dec 13;21(1):305. doi: 10.1186/s13054-017-1882-z.
10
The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.肾素-血管紧张素系统的血管保护轴：心血管、高血压和肾脏疾病中的生理相关性和治疗意义。
Pharmacol Res. 2017 Nov;125(Pt A):21-38. doi: 10.1016/j.phrs.2017.06.005. Epub 2017 Jun 12.
Zotero 插件